Dr. Reddy’s Laboratories Ltd ADR (RDY)vsViatris Inc (VTRS)
RDY
Dr. Reddy’s Laboratories Ltd ADR
$13.87
+3.12%
HEALTHCARE · Cap: $11.20B
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Dr. Reddy’s Laboratories Ltd ADR generates 2318% more annual revenue ($345.83B vs $14.30B). RDY leads profitability with a 16.4% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. RDY earns a higher WallStSmart Score of 53/100 (C-).
RDY
Buy53
out of 100
Grade: C-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-190.0%
Fair Value
$4.90
Current Price
$13.87
$8.97 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Reasonable price relative to book value
Generating 3.6B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
4.4% revenue growth
Weak financial health signals
Expensive relative to growth rate
Earnings declined 14.3%
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : RDY
The strongest argument for RDY centers on Altman Z-Score, Debt/Equity, Price/Book. Profitability is solid with margins at 16.4% and operating margin at 16.4%.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : RDY
The primary concerns for RDY are Revenue Growth, Piotroski F-Score, PEG Ratio.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
RDY profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
VTRS is growing revenue faster at 5.0% — sustainability is the question.
RDY generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
RDY scores higher overall (53/100 vs 50/100), backed by strong 16.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dr. Reddy’s Laboratories Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?